Holen Sie sich die Stockscreener-App
20.35
1.88%
-0.39
Handel nachbörslich:
19.95
-0.40
-1.97%
Crescent Biopharma Inc Aktie (CBIO) Neueste Nachrichten
CBIO: Four clinical studies launching in 2024 set up a data-rich 2027 for oncology pipeline decisions - TradingView
Crescent Biopharma (CBIO) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Crescent Biopharma to present CR-001 trial data at ASCO meeting - Investing.com Nigeria
Crescent Biopharma to present CR-001 trial data at ASCO meeting By Investing.com - Investing.com South Africa
Crescent Biopharma Announces Ongoing ASCEND Phase 1/2 Clinical Trial of CR-001 for Multiple Solid Tumor Types with Initial Data Expected in 2027 - Quiver Quantitative
Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 ... - Caledonian Record
Crescent cancer trial takes CR-001 to ASCO 2026, first data expected in 2027 - Stock Titan
Tang Capital entities disclose 1,160,000-share stake in Crescent Biopharma (CBIO) - Stock Titan
New Forecasts: Here's What Analysts Think The Future Holds For Crescent Biopharma, Inc. (NASDAQ:CBIO) - 富途牛牛
Balyasny entities disclose 1.51M shares in Crescent Biopharma (CBIO) - Stock Titan
Crescent Biopharma Announces Grants of Inducement Awards - ChartMill
Crescent Biopharma gives 5 new hires options on 129,075 shares - Stock Titan
Number of shareholders of Crescent Biopharma, Inc. – NASDAQ:CBIO - TradingView
CBIO Crescent Bio jumps 4% as Q1 loss beats estimates by 27%, pipeline progress lifts investor confidence.Trading Community - Newser
Rainbows and Unicorns: Crescent Biopharma, Inc. (NASDAQ:CBIO) Analysts Just Became A Lot More Optimistic - simplywall.st
Crescent Biopharma lines up 3 May conference webcasts for investors - Stock Titan
Crescent Biopharma to Present at May Investor Conferences - ChartMill
Crude Oil Down 3%; Chevron Posts Mixed Q1 Results - Sahm
H.C. Wainwright Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Crescent Biopharma (NASDAQ:CBIO) Trading Up 8.3%Here's Why - MarketBeat
The numbers behind Crescent Bio (CBIO) stock nobody talks about (Technical Weakness) 2026-05-03 - newser.com
MSN Money - MSN
Stifel Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Cuts Target Price to $30 - Moomoo
Nasdaq Jumps Over 1%; Exxon Mobil Posts Upbeat Revenue - Benzinga
Crescent Biopharma Down Over 16%, On Pace for Largest Percent Decrease Since July 2024 -- Data Talk - Moomoo
Crescent Biopharma Inc (CBIO) - MSN
Analysts Offer Insights on Healthcare Companies: MBX Biosciences, Inc. (MBX), Cytokinetics (CYTK) and Crescent Biopharma (CBIO) - The Globe and Mail
CBIO Price Today: Crescent Biopharma, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
12 Health Care Stocks Moving In Friday's Pre-Market SessionAkanda (NASDAQ:AKAN), Akari Therapeutics (N - Benzinga
Wedbush Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Maintains Target Price $27 - Moomoo
A Quick Look at Today's Ratings for Crescent Biopharma(CBIO.US), With a Forecast Between $27 to $35 - Moomoo
Crescent Biopharma: Q1 Earnings Snapshot - Barchart.com
Crescent Biopharma (CBIO) registers 19.58M ordinary shares for resale - Stock Titan
Crescent Biopharma (NASDAQ: CBIO) posts Q1 2026 loss and oncology pipeline update - Stock Titan
Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights - GlobeNewswire
Crescent Biopharma (CBIO) Q1 2026 results show $23.3M loss and $189M cash - Stock Titan
Crescent Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Crescent lines up 2027 cancer trial readouts with cash into 2028 - Stock Titan
Crescent Biopharma (NASDAQ:CBIO) Shares Cross Above 200-Day Moving AverageShould You Sell? - MarketBeat
Crescent Biopharma Grants Equity Inducement Awards to New Employees as Part of 2025 Incentive Plan - Quiver Quantitative
Stifel Initiates Coverage of Crescent Biopharma (CBIO) with Buy Recommendation - MSN
Crescent Bio (CBIO) Stock: Is It Losing Momentum | Q4 2025: Better Than ExpectedWall Street Picks - Xã Châu Thành
Analysts Are Bullish on These Healthcare Stocks: Guardant Health (GH), Crescent Biopharma (CBIO) - The Globe and Mail
CRESCENT BIOPHARMA, INC. ($CBIO) CEO & Director 2025 Pay Revealed - Quiver Quantitative
Form DEFA14A CRESCENT BIOPHARMA, INC. - StreetInsider
Crescent Biopharma (NASDAQ: CBIO) outlines 2026 AGM votes on board, pay and auditor - Stock Titan
Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Piper Sandler Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Crescent Biopharma (NASDAQ:CBIO) Shares Pass Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Corcept Therapeutics (NASDAQ:CORT) vs. Crescent Biopharma (NASDAQ:CBIO) Head to Head Review - Defense World
Crescent Biopharma Stock Surges 86%, With A 7-Day Winning Spree - Trefis
Crescent Biopharma Stock On Fire: Up 86% With 7-Day Winning Streak - Trefis
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):